In 2023, the Business Enterprise R&D Expenditure in Human Health Activities in Germany was valued at approximately €8.5 million. Forecasts indicate a progressive increase, reaching €9.9 million in 2024, and further rising to €15.81 million by 2028. This represents a Compound Annual Growth Rate (CAGR) of about 13.64% from 2024 to 2028, underscoring a robust upward trend driven by increasing demand for healthcare innovations.
Year-on-year growth rates over the forecasted period reflect sustained investments in the sector, with notable increases each year as follows:
- 2024 to 2025: 15.05%
- 2025 to 2026: 13%
- 2026 to 2027: 11.51%
- 2027 to 2028: 10.17%
Future trends to watch include advancements in biotechnology and personalized medicine, driven by increasing patient-centric approaches and governmental support in research and development. These factors are poised to accelerate the expansion of R&D activities further.
